A new drug seeking to treat irritability associated with Autism Spectrum Disorder (ASD) could soon be making its way to clinical trials in healthy volunteers after Zelira Therapeutics (ASX: ZLD) concluded a positive round of discussions with the United States Food and Drug Administration (FDA) on a study design. The proposed clinical trials are for
Read MoreCan you make autistic people less autistic? Neurotech International (ASX: NTI) believes so based on data published from their Phase II/III clinical trial of NTI-164 which aims to treat Autism Spectrum Disorder (ASD). ASD is a complex neurodevelopmental condition that can manifest in various ways. From challenges in social interactions, repetitive behaviours, and restricted interests,
Read MoreThe content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.